16 results on '"Sophie Blanchi"'
Search Results
2. Immunization Catch-Up for Newly Arrived Migrants in France: A Cross-Sectional Study among French General Practitioners
- Author
-
Sohela Moussaoui, Anne Marie Aurousseau, Sylvain Nappez, Julian Cornaglia, Gaylord Delobre, Sophie Blanchi, Louise Luan, Stéphanie Vandentorren, Olivier Bouchaud, Odile Launay, Louise Nutte, Roxane Liard, Mariela Skendi, Matthieu Mechain, and Nicolas Vignier
- Subjects
family health ,immigrants ,transients and migrants ,vaccine ,catch-up ,Medicine - Abstract
Background: Migrants often undergo an incomplete vaccination program in regards to the French recommendations. The aim of this study was to evaluate the practices of French General Practitioners’ (GPs) in terms of catch-up vaccination. Methods: A cross-sectional study was carried-out in 2017–2018 in France. An online questionnaire was disseminated by email through scholarly societies to GPs involved in the care and the vaccination of migrants. Analyses included univariate and multivariate analysis with a logistic regression model. Results: A total of 216 GPs completed the survey. A majority identified themselves with an average level regarding the prevention of infectious diseases among migrant populations (56.7%) and confirmed this is part of their daily practice (83.3%). The majority of respondents do not perform more than two injections on the same day. When compared to GPs working in health centres, those with a private practice are more likely to report returning to a full primary vaccination schedule (adjusted OR = 2.90, 95% CI [1.29–6.53]). Aside from the serology for hepatitis B and to a lesser extent for measles, other pre-vaccination serologies were not frequently used by GPs. When a migrant declares to be up-to-date with his immunisations, only 56.5% of doctors consider this information reliable. Conclusions: This study clarified the vaccination practices of GPs receiving migrant patients in consultation and showed its heterogeneity. An important need for benchmarks has been identified and these results were used for the elaboration of the French guidelines on vaccines catch-up.
- Published
- 2021
- Full Text
- View/download PDF
3. Impact of a Catch-Up Strategy of DT-IPV Vaccination during Hospitalization on Vaccination Coverage among People Over 65 Years of Age in France: The HOSPIVAC Study (Vaccination during Hospitalization)
- Author
-
Sophie Blanchi, Justine Vaux, Jean Marc Toqué, Ludovic Hery, Servane Laforest, Giorgina Barbara Piccoli, and Nicolas Crochette
- Subjects
vaccination coverage ,DT-IPV vaccine ,catch-up vaccination ,elderly ,Medicine - Abstract
In France, diphtheria tetanus and inactivated polio vaccine (DT-IPV) coverage and immunization are insufficient in the elderly and decrease with age. The principal objective of this study was to assess the impact of a strategy of catch-up DT-IPV vaccination during hospitalization in people over the age of 65 years in central France (the Sarthe region). We performed a prospective, single-center, cluster-randomized study (four hospital wards). We included patients aged ≥65 years, without mental impairment, contraindication and who accepted to participate, hospitalized in the internal medicine wards in Le Mans Hospital from 28 May 2018 to 27 May 2019. The DT-IPV vaccination status of the patients was determined at inclusion and the wards were randomized (intervention and control). In the intervention group, vaccination was up-dated during hospitalization. In case of temporary contraindication, vaccination was prescribed at hospital discharge. Patients hospitalized in the control wards received oral information only. Final immunization status was determined by calling the patient’s general practitioner two months after hospital discharge. One hundred and fifty seven patients were included: 73 in the intervention and 84 in the control arm. Baseline immunization coverage was 46.5%. Vaccination coverage increased from 56.2% to 80.8% in the intervention group and from 38.1% to 40.5% in the control group (p < 0.001). Having received sufficient information from the general practitioner was the only factor associated with vaccination being up-to-date in uni- and multivariate analysis: OR = 5.07 [2.45–10.51]. In a setting of low vaccination coverage DT-IPV vaccination during hospitalization is an effective catch-up strategy.
- Published
- 2020
- Full Text
- View/download PDF
4. Impact of vaccination on the presence and severity of symptoms of hospitalised patients with an infection by the omicron variant (B.1.1.529) of the SARS-cov-2 (subvariant BA.1)
- Author
-
Guillaume Beraud, Laura Bouetard, Rok Civljak, Jocelyn Michon, Necla Tulek, Sophie Lejeune, Romain Millot, Aurélie Garchet-Beaudron, Maeva Lefebvre, Petar Velikov, Benjamin Festou, Sophie Abgrall, Ivan Kresimir Lizatovic, Aurélie Baldolli, Huseyin Esmer, Sophie Blanchi, Gabrielle Froidevaux, Nikol Kapincheva, Jean-François Faucher, Mario Duvnjak, Elçin Afşar, Luka Švitek, Saliha Yarimoglu, Rafet Yarimoglu, Cécile Janssen, and Olivier Epaulard
- Subjects
Microbiology (medical) ,Infectious Diseases ,Breakthrough infection ,Omicron ,SARS-CoV-2 ,Severity ,Vaccine ,General Medicine - Abstract
ObjectivesThe emergence of SARS-CoV-2 variants raised questions over the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalised patients.MethodsWe conducted an international, multicentric, retrospective study in 14 centres (Bulgaria, Croatia, France, Turkey). We collected data on patients hospitalised ≥24 hours between 01/12/2021 and 03/03/2022, with PCR-confirmed infection at a time of exclusive Omicron circulation, with hospitalisation related or not to the infection. Patients who had received prophylaxis by monoclonal antibodies were excluded. Patients were considered fully vaccinated if they had received at least 2 injections of either mRNA and/or ChAdOx1-S, or 1 injection of Ad26.CoV2-S vaccines.ResultsAmong the 1215 patients (median [IQR] age 73.0 [57.0; 84.0]; 51.3% males), 746 (61.4%) were fully vaccinated. In multivariate analysis, being vaccinated was associated with lower 28-day mortality (RR=0.50 [0.32-0.77]), ICU admission (R=0.40 [0.26-0.62], and oxygen requirement (RR=0.34 [0.25-0.46]), independently of age and comorbidities. When co-analysing these Omicron patients with 948 Delta patients from a study we recently conducted, Omicron infection was associated with lower 28-day mortality (RR=0.53 [0.37-0.76]), ICU admission (R=0.19 [0.12-0.28], and oxygen requirements (RR=0.50 [0.38-0.67]), independently of age, comorbidities and vaccination status.ConclusionsmRNA- and adenovirus-based vaccines have remained effective on severity of Omicron SARS-CoV-2 infection. Omicron is associated with a lower risk of severe forms, independently of vaccination and patient characteristics.
- Published
- 2022
5. Measles seroprevalence in human immunodeficiency virus-infected adults born in the era of measles vaccination
- Author
-
Maeva, Lefebvre, Solène, Secher, Sabelline, Bouchez, Yves-Marie, Vandamme, Pascale, Fialaire, Sophie, Leautez, Sophie, Blanchi, Christophe, Michau, Marianne, Coste-Burel, Cécile, Brunet-Cartier, Véronique, Reliquet, Antoine, Gregoire, François, Raffi, and Clotilde, Allavena
- Subjects
Adult ,Cross-Sectional Studies ,Seroepidemiologic Studies ,Measles Vaccine ,Vaccination ,HIV ,Humans ,Female ,HIV Infections ,Antibodies, Viral ,Measles - Abstract
Widespread use of the measles vaccine should lead to the elimination of this disease. Here, we study the seroprevalence of measles in a cohort of adults living with HIV born after the introduction of measles vaccine in France and attempt to identify risk factors for the absence of serum measles antibody.In this multi-centre cross-sectional study, adult outpatients born after 1980 were screened for the presence of measles IgG antibody. Demographic and clinical data were obtained from the standardized electronic medical record system. Univariate and multivariate logistic regressions were performed to identify factors associated with the absence of measles antibodies.Between April 2019 and April 2020, 648 participants were enrolled. The median age was 33 years, 53.6% were born outside of France, and 74% were considered as socially deprived. Plasma HIV RNA was undetectable in 86% of patients. Among 603 evaluable patients, measles serology was positive in 87.2%. Only 81.8% of the patients with documented vaccination tested positive for measles IgG. Younger age was significantly associated with the absence of measles serum antibodies ( P = 0.004 for each 10-year lower), as was birth in France ( P 0.001) and absence of social vulnerability ( P = 0.04).The current study revealed a low seroprevalence of measles compared with that previously reported in France 6 years earlier and to the expected rate to achieve herd immunity. Checking vaccination record should be systematically carried out in patients living with HIV to fill the immunity gaps.
- Published
- 2022
6. Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis
- Author
-
Marine Dekervel, Marine Asfar, Sophie Blanchi, Virginie Besson, Anne-Sophie Garnier, Giorgina Barbara Piccoli, Lise-Marie Pouteau, Jean-François Augusto, Massimo Torreggiani, Chloé Mellaza, Alexandra Ducancelle, Jean-Paul Imiela, Amaury Dujardin, Nicolas Henry, Axelle Paquin, Adaptation et diversité en milieu marin (AD2M), Station biologique de Roscoff (SBR), Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Le Mans (CH Le Mans), Centre Hospitalier de Laval (CH Laval), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service de Néphrologie-Dialyse-Transplantation [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), and Université d'Angers (UA)
- Subjects
medicine.medical_specialty ,SARS-Cov-2 ,[SDV]Life Sciences [q-bio] ,Population ,030204 cardiovascular system & hematology ,immunogenicity ,Immunoglobulin G ,Serology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Seroconversion ,education ,AcademicSubjects/MED00340 ,030203 arthritis & rheumatology ,Transplantation ,education.field_of_study ,BNT162b2 vaccine ,biology ,business.industry ,Immunogenicity ,COVID-19 ,3. Good health ,Vaccination ,haemodialysis ,Nephrology ,Cohort ,biology.protein ,Original Article ,Antibody ,business - Abstract
Background Humoral response against sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after two doses of BNT162b2 (Pfizer-BioNTech) has been proven to be less intense in maintenance dialysis patients as compared with healthy subjects, leading the French authorities to recommend a third injection in this population. Here we investigated the response to the third injection in two cohorts of haemodialysis (HD) patients. Methods Data from two prospective observational cohorts were collected. In the first (‘systematic’) cohort, patients from two HD centres (n = 66) received a third injection of BNT162b2, regardless of the response after two injections. In the second (‘conditional’) cohort, the injection was only prescribed to patients (n = 34) with no or low response to the previous two doses. In both cohorts, the third dose was injected 1–2 months after the second dose. Serology was performed after the second and third doses to assess anti-Spike immunoglobulin G (S IgG) antibody titre. Results In the systematic cohort, anti-S IgG was found in 83.3 and 92.4% of patients after the second and third doses of BNT162b2, respectively. In this cohort, 6/11 (54.5%) and 20/21 (95.2%) patients switched from non-responder to low responder and from low responder to high responder, respectively. In low and high responders to two doses, 50/55 (90.9%) at least doubled their anti-S IgG titre. Similar trends were observed in the conditional cohort. Conclusions In maintenance HD patients, humoral response against SARS-CoV-2 was boosted after a third dose of BNT162b2, allowing seroconversion in more than half of non-responders. These data may support an intensified vaccination protocol with a third dose of BNT162b2 in dialysis patients., Graphical Abstract Graphical Abstract
- Published
- 2021
7. Cat on a hot tin roof (a nephrology zebra)
- Author
-
Samuel Wacrenier, Giorgina Barbara Piccoli, Jean Philippe Coindre, and Sophie Blanchi
- Subjects
Nephrology ,medicine.medical_specialty ,Pathology ,business.industry ,Acute Kidney Injury ,Zebra (medicine) ,3-MMC ,Tin ,Internal medicine ,Cathinone drug ,medicine ,Humans ,business ,Art in the Ward - Published
- 2021
8. Immunization Catch-Up for Newly Arrived Migrants in France: A Cross-Sectional Study among French General Practitioners
- Author
-
Sylvain Nappez, Nicolas Vignier, Julian Cornaglia, Sohela Moussaoui, Matthieu Mechain, Olivier Bouchaud, Roxane Liard, Louise Luan, Louise Nutte, Sophie Blanchi, Odile Launay, Stéphanie Vandentorren, Mariela Skendi, Anne Marie Aurousseau, Gaylord Delobre, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), CHU Bordeaux [Bordeaux], CHU Amiens-Picardie, Centre Hospitalier Saint Jean de Perpignan, Réseau Louis Guilloux (RLG), Centre Hospitalier Le Mans (CH Le Mans), Centre Hospitalier de Melun (CHM), Laboratoire éducations et promotion de la santé (LEPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord, CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], HAL-SU, Gestionnaire, Centre Hospitalier de Melun, Laboratoire Educations et Pratiques de Santé (LEPS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP)-Groupe hospitalier Broca-Hôpital Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
medicine.medical_specialty ,Multivariate analysis ,Cross-sectional study ,media_common.quotation_subject ,Immunology ,Immigration ,education ,transients and migrants ,Computer-assisted web interviewing ,Logistic regression ,Measles ,Article ,03 medical and health sciences ,0302 clinical medicine ,[SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology ,vaccine ,Drug Discovery ,Medicine ,Pharmacology (medical) ,030212 general & internal medicine ,media_common ,Pharmacology ,catch-up ,business.industry ,family health ,immigrants ,030208 emergency & critical care medicine ,medicine.disease ,3. Good health ,Vaccination ,Infectious Diseases ,Private practice ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Family medicine ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology ,business - Abstract
International audience; Background: Migrants often undergo an incomplete vaccination program in regards to the French recommendations. The aim of this study was to evaluate the practices of French General Practitioners’ (GPs) in terms of catch-up vaccination. Methods: A cross-sectional study was carried-out in 2017–2018 in France. An online questionnaire was disseminated by email through scholarly societies to GPs involved in the care and the vaccination of migrants. Analyses included univariate and multivariate analysis with a logistic regression model. Results: A total of 216 GPs completed the survey. A majority identified themselves with an average level regarding the prevention of infectious diseases among migrant populations (56.7%) and confirmed this is part of their daily practice (83.3%). The majority of respondents do not perform more than two injections on the same day. When compared to GPs working in health centres, those with a private practice are more likely to report returning to a full primary vaccination schedule (adjusted OR = 2.90, 95% CI [1.29–6.53]). Aside from the serology for hepatitis B and to a lesser extent for measles, other pre-vaccination serologies were not frequently used by GPs. When a migrant declares to be up-to-date with his immunisations, only 56.5% of doctors consider this information reliable. Conclusions: This study clarified the vaccination practices of GPs receiving migrant patients in consultation and showed its heterogeneity. An important need for benchmarks has been identified and these results were used for the elaboration of the French guidelines on vaccines catch-up.
- Published
- 2021
9. Two episodes of severe acute respiratory syndrome coronavirus 2 infection in a patient on chronic hemodialysis: a note of caution
- Author
-
B. Ebikili, Giorgina Barbara Piccoli, Sophie Blanchi, and Massimo Torreggiani
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Nephrology ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.medical_treatment ,medicine ,Chronic hemodialysis ,business ,Virology ,Letter to the Editor ,Dialysis ,Asymptomatic Diseases - Published
- 2021
- Full Text
- View/download PDF
10. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won
- Author
-
H. Fessi, Antioco Fois, Massimo Torreggiani, Sophie Blanchi, and Giorgina Barbara Piccoli
- Subjects
COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Dialysis patients ,Renal Dialysis ,medicine ,Humans ,Renal replacement therapy ,RNA, Messenger ,Letter to the Editor ,BNT162 Vaccine ,Messenger RNA ,business.industry ,SARS-CoV-2 ,Vaccination ,COVID-19 ,Virology ,Antibodies, Neutralizing ,Renal Replacement Therapy ,Antibody response ,Nephrology ,Antibody Formation ,Dialysis (biochemistry) ,business - Published
- 2021
11. The effectiveness of the BuzzyⓇ device to reduce or prevent pain in children undergoing needle-related procedures: The results from a prospective, open-label, randomised, non-inferiority study
- Author
-
Katia Lescop, Valéry-Pierre Riche, Valérie Briend-Godet, Sandrine Coudol, Emmanuelle Cartron, Paola Delbos, Christian Brechet, Christelle Volteau, Isabelle Joret, Sophie Blanchi, Annastasia Galivel-Voisine, Centre hospitalier universitaire de Nantes (CHU Nantes), CHD Vendée - Hôpital Les Oudairies [La Roche sur Yon], MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Centre Hospitalier Le Mans (CH Le Mans), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR des Sciences Pharmaceutiques et Biologiques (Nantes Université - UFR Pharmacie), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), CCSD, Accord Elsevier, and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
- Subjects
medicine.medical_specialty ,Lidocaine ,[SDV]Life Sciences [q-bio] ,03 medical and health sciences ,0302 clinical medicine ,Clinical endpoint ,Buzzy(Ⓡ) ,Medicine ,030212 general & internal medicine ,General Nursing ,Venipuncture ,030504 nursing ,business.industry ,Vaccination ,Pain scale ,Pain management ,Lidocaine Patch ,Screaming ,[SDV] Life Sciences [q-bio] ,Paediatric ,Physical therapy ,Open label ,medicine.symptom ,Needle-related procedure ,0305 other medical science ,business ,medicine.drug - Abstract
Background Pain from needle-related procedures in children can alter pain perception, increase pain sensitivity, and generate inappropriate pain responses. Currently pain management includes the use of lidocaine-containing patches, which is complicated to manage in a busy medical setting such as a vaccination centre. We assessed the BuzzyⓇ device, which combines vibration and cold, to manage pain in children undergoing a needle-related procedure, compared to the standard lidocaine patch. Design Prospective, open-label, non-inferiority trial. Setting The vaccination centres of three university hospitals in France. Participants French speaking children aged 4–15 requiring a needle-related procedure (vaccination or venepuncture) were eligible. Principal exclusion criteria were allergy or sensitivity to the lidocaine patch. Methods Children were randomly allocated (1:1) to use either the BuzzyⓇ device or the lidocaine patch during the needle-related procedure. The lidocaine patch was applied to the puncture site for the hour prior to the intervention. The BuzzyⓇ device was applied to the puncture site for 30 s and then moved 5 cm along the limb during the procedure. The refrigerated wings were detached if they bothered the child. The child assessed their pain using the validated Revised Faces Pain Scale. The revised faces pain scale comprised six facial expressions from 0, normal “no pain” to 10, a screaming face “severe pain” (2 points/face). The primary endpoint was the average pain score recorded by the child. The study aimed to test the non-inferiority of BuzzyⓇ. Results Overall 219 participants were randomised. The primary outcome was assessed in 215 children: 108 in the BUZZY group (43% asked for the refrigerated wings were de to be detatched before the end of the procedure) and 107 in the PATCH group. The baseline characteristics were similar between the study groups with an average age of 9 (range: 4.08–15.81). The average needle-related pain was 2.04 in the BUZZY group and 1.42 in the PATCH group. The average difference between the children's assessments in the groups was 0.62, thus faling to demonstrate non-inferiority. Conclusions Our study failed to show that the BuzzyⓇ device was not inferior to the lidocaine patch in managing pain in children undergoing needle-related procedures. Tweetable abstract: Pain management in children undergoing a needle-related procedure vaccination: which efficacy for BuzzyⓇ device as an alternative to lidocaine patch? A prospective, randomised study.
- Published
- 2021
12. COVID-19 Vaccine Hesitancy in Patients on Dialysis in Italy and France
- Author
-
H. Fessi, Alessio Pili, Ciro Esposito, Giorgina Barbara Piccoli, Antoine Chatrenet, Sophie Blanchi, Massimo Torreggiani, Nicola Lepori, Elisabetta Versino, Giuseppe Sileno, Antioco Fois, Giovanna Bianco, Antonello Pani, Linda Njandjo, Béatrice Mazé, Vittoria Esposito, Gianfranca Cabiddu, P.A. Michel, and Marta Arazzi
- Subjects
Univariate analysis ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Influenza vaccine ,SARS-CoV-2 ,medicine.medical_treatment ,COVID-19 ,Disease ,Vaccine efficacy ,Vaccination ,Clinical Research ,Nephrology ,vaccine ,Health care ,medicine ,dialysis ,hesitancy ,business ,Dialysis ,Demography - Abstract
Introduction Patients on dialysis (HDPs) are a category at high risk from COVID-19 and thus a high-priority group for vaccination. COVID-19 vaccine hesitancy has been a concern since the availability of the first vaccine. The objective of this study was to determine hesitancy rates and factors associated with hesitancy toward COVID-19 vaccination in HDP. Methods HDP were surveyed with an ad hoc questionnaire in 4 large dialysis facilities in Europe: Le Mans and Paris, in France, and Cagliari and Pavia, in Italy. The questionnaire explored different domains associated with vaccine hesitancy, such as perception of disease severity, sources of information about the vaccine and the disease, and confidence in the health care system. Results A total of 417 patients (average age 69 years, 60% men) agreed to answer the questionnaire. Hesitancy was associated with younger age (P = 0.003), lower perception of disease severity (P < 0.001) and vaccine efficacy (P < 0.001), and lower trust in vaccination (P < 0.001) and in the health care system and scientists (P < 0.001) in the univariate analysis. In the multivariate models, concerns about side effects (P = 0.004) and vaccine efficacy (P < 0.001) and living in France (P = 0.04) remained associated with higher vaccine hesitancy, whereas having received an influenza vaccine (P = 0.032) and trusting scientists (P = 0.032) were associated with a more positive attitude toward vaccination. Conclusions HDPs have a good understanding of the risks associated with COVID-19. Vaccine hesitancy was not associated with educational level, age, or gender but rather with lack of confidence in vaccine efficacy and concerns about safety. HDPs were quite skeptical about the health care system but generally trusted scientists.
- Published
- 2021
13. Necrotizing cellulitis secondary to Aspergillus in a patient with metastatic breast cancer treated with systemic steroids and trastuzumab
- Author
-
Sophie Blanchi, Georgina Piccoli, Lucia Perez, Pascale Penn, Constance Josse, and Nathalie Beneton
- Subjects
Microbiology (medical) ,Pathology ,medicine.medical_specialty ,Breast Neoplasms ,Infectious and parasitic diseases ,RC109-216 ,Aspergillosis ,Aspergillus fumigatus ,Trastuzumab ,Necrotizing cellulitis ,Humans ,Medicine ,Aspergillus ,biology ,business.industry ,Cellulitis ,General Medicine ,medicine.disease ,biology.organism_classification ,Metastatic breast cancer ,Infectious Diseases ,Female ,Steroids ,business ,medicine.drug - Published
- 2021
14. Impact of a Catch-Up Strategy of DT-IPV Vaccination during Hospitalization on Vaccination Coverage among People Over 65 Years of Age in France: The HOSPIVAC Study (Vaccination during Hospitalization)
- Author
-
Ludovic Hery, Servane Laforest, Nicolas Crochette, Justine Vaux, Jean Marc Toqué, Sophie Blanchi, Giorgina Barbara Piccoli, Centre Hospitalier Le Mans (CH Le Mans), and Service Néphrologie [CH Le Mans]
- Subjects
Pediatrics ,medicine.medical_specialty ,Multivariate analysis ,[SDV]Life Sciences [q-bio] ,Immunology ,lcsh:Medicine ,complex mixtures ,elderly ,Article ,03 medical and health sciences ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,030225 pediatrics ,Intervention (counseling) ,Drug Discovery ,medicine ,Catch-up vaccination ,DT-IPV vaccine ,Elderly ,Vaccination coverage ,Pharmacology (medical) ,030212 general & internal medicine ,Contraindication ,Pharmacology ,vaccination coverage ,Tetanus ,business.industry ,Diphtheria ,[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology ,catch-up vaccination ,lcsh:R ,social sciences ,medicine.disease ,3. Good health ,Vaccination ,Infectious Diseases ,Immunization ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business - Abstract
In France, diphtheria tetanus and inactivated polio vaccine (DT-IPV) coverage and immunization are insufficient in the elderly and decrease with age. The principal objective of this study was to assess the impact of a strategy of catch-up DT-IPV vaccination during hospitalization in people over the age of 65 years in central France (the Sarthe region). We performed a prospective, single-center, cluster-randomized study (four hospital wards). We included patients aged &ge, 65 years, without mental impairment, contraindication and who accepted to participate, hospitalized in the internal medicine wards in Le Mans Hospital from 28 May 2018 to 27 May 2019. The DT-IPV vaccination status of the patients was determined at inclusion and the wards were randomized (intervention and control). In the intervention group, vaccination was up-dated during hospitalization. In case of temporary contraindication, vaccination was prescribed at hospital discharge. Patients hospitalized in the control wards received oral information only. Final immunization status was determined by calling the patient&rsquo, s general practitioner two months after hospital discharge. One hundred and fifty seven patients were included: 73 in the intervention and 84 in the control arm. Baseline immunization coverage was 46.5%. Vaccination coverage increased from 56.2% to 80.8% in the intervention group and from 38.1% to 40.5% in the control group (p <, 0.001). Having received sufficient information from the general practitioner was the only factor associated with vaccination being up-to-date in uni- and multivariate analysis: OR = 5.07 [2.45&ndash, 10.51]. In a setting of low vaccination coverage DT-IPV vaccination during hospitalization is an effective catch-up strategy.
- Published
- 2020
15. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
- Author
-
Vincent Dubée, Pierre-Marie Roy, Bruno Vielle, Elsa Parot-Schinkel, Odile Blanchet, Astrid Darsonval, Caroline Lefeuvre, Chadi Abbara, Sophie Boucher, Edouard Devaud, Olivier Robineau, Patrick Rispal, Thomas Guimard, Emma d’Anglejean, Sylvain Diamantis, Marc-Antoine Custaud, Isabelle Pellier, Alain Mercat, Antoine Brangier, Philippe Codron, Jean Michel Lemée, Virginie Pichon, Robin Dhersin, Geoffrey Urbanski, Christian Lavigne, Roxane Courtois, Hélène Danielou, Jonathan Lebreton, Rémi Vatan, Nicolas Crochette, Jean-Baptiste Lainé, Lucia Perez, Sophie Blanchi, Hikombo Hitoto, Louis Bernard, François Maillot, Sylvain Marchand Adam, Jean-Philippe Talarmin, Emeline Gaigneux, Pauline Motte-Vincent, Marine Morrier, Dominique Merrien, Yves Bleher, Maxime Flori, Amélie Ducet-Boiffard, Orane Colin, Ronan Février, Pauline Thill, Macha Tetart, François Demaeght, Barthelemy Lafond-Desmurs, Maxime Pradier, Agnes Meybeck, Marjorie Picaud, Thierry Prazuck, Guillaume Chapelet, Agnès Rouaud, Paul Le Turnier, Simon Sunder, Aurélien Lorleac'h, Christophe Dollon, Antoine Jacquet, Francois Le Vely, Pierre Gazeau, Séverine Ansart, Hélène Roger, François Laterza, Rodolphe Buzelé, Fella Tahmi, Raphael Lepeule, Karine Lacombe, Bénédicte Lefebvre, Thomas Célarier, Amandine Gagneux-Brunon, Elisabeth Botelho-Nevers, Marc Bernard, Camille Garnier, Morgane Mourguet, Gregory Pugnet, Sara Vienne-Noyes, Guillaume Martin-Blondel, Pierre Delobel, Gaspard Grouteau, Alexa Debard, Laurent Guilleminault, Pauline Arias, Catherine Chakvetadze, Clara Flateau, Aude Kopp, Alain Putot, Jeremy Barben, Suzanne Mouries Martin, Valentine Nuss, Lionel Piroth, Yann-Erick Claessens, Veronique Hentgen, Martin Martinot, Maxime Bach-Bunner, Thomas Bonijoly, Simon Gravier, Jean-Marc Michel, Mathilde Andreu, Mélanie Roriz, Aurélie Baldolli, Julia Brochard, Olivier Grossi, Samuel Pineau, Josselin Brisset, Edouard Desvaux, Guillaume Gondran, Jean-François Faucher, Paul-Antoine Quesnel, Holy Bezanahary, Clément Danthu, Blandine Gutierrez, Kim Ly, Yannick Simonneau, Anne Cypierre, Pauline Pinet, Hélène Durox, Sophie Ducroix-Roubertou, Claire Genet, Guillaume Beraud, Gwenael Le Moal, Blandine Rammaert, Jean-Philippe Lanoix, Claire Andrejak, Cédric Joseph, Sandrine Soriot-Thomas, Robin Dhote, Sébastien Abad, Ruben Benainous, Jean-François Boitiaux, Guillaume Briend, Celine Gonfroy, Stanislas Harent, Aurore Lagrange, Alina Tone, Laura Wayenberg, Sophie Desoutter, Nicolas Ettahar, Thomas Gey, Vincent Leroy, Sacha Gaillard, Andrea Toma, Amaury Broussier, Sandrine Etienne, Yann Spivac, Benoit Martha, Nathalie Roch, Pierre Diaz, Danièle N’guyen Baranoff, Stanislas Rebaudet, François Jourda, Valérie Zeller, Boris Bienvenu, Arnaud Boyer, Marie Briet, Bertrand Guidet, Patrick Mismetti, Eric Vicaut, Olivier Sanchez, Philippe Girard, Antoine Elias, Francis Couturaud, Béatrice Gable, Sybille Lazareff, Loïc Carballido, Catherine Hue, Jean-Marie Chrétien, Adrien Goraguer, Lucie van Eeckhoutte, ATOMycA (CRCINA-ÉQUIPE 6), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Ressources Biologiques [CHU d'Angers] (CRB CHU d'Angers BB-0033-00038), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Département de Pharmacie [CHU d'Angers], Laboratoire de virologie [CHU Angers], Département de Pharmacologie-Toxicologie [CHU Angers], Centre Hospitalier René Dubos [Pontoise], Centre Hospitalier Tourcoing, Service de Médecine Interne [Agen], Centre Hospitalier d'Agen, Centre Hospitalier Départemental Vendée (CHDV), Centre Hospitalier de Versailles André Mignot (CHV), Groupe Hospitalier Sud, Université d'Angers (UA), HYCOVID study group, HYCOVID investigators, Angers University Hospital, Cholet Hospital, Laval Hospital, Le Mans Hospital, Tours University Hospital, Quimper Hospital, La Roche sur Yon Hospital, Tourcoing Hospital, Orléans Hospital, Nantes University Hospital, Niort Hospital, Lorient Hospital, Brest University Hospital, Cherbourg Hospital, Saint-Brieuc Hospital, Créteil – APHP University Hospital, Saint-Antoine – APHP University Hospital, Saint-Etienne University Hospital, Toulouse University Hospital, Melun Hospital, Dijon University Hospital, Princesse Grace – Monaco Hospital, Versailles Hospital, Colmar Hospital, Agen-Nerac Hospital, Caen University Hospital, Saint-Nazaire Hospital, Nantes – Confluent Hospital, Limoges University Hospital, Poitiers University Hospital, Amiens University Hospital, Bobigny – APHP University Hospital, Cergy-Pontoise Hospital, Valencienne Hospital, Valencienne – Clinique Tessier Hospital, Henri-Mondor – APHP University Hospital, Chalon-sur-Saône Hospital, Marseille European Hospital, Auxerre Hospital, Diaconnesses Croix-Saint-Simon Hospital, Marseille – Saint Joseph Hospital, Composition of the HYCOVID management team, Steering committee, Independant data safety and monitoring board, Independent adjudication of clinical events committee, Study management Coordination, Data management., Bernardo, Elizabeth, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Service des maladies infectieuses et tropicales [CHU Angers], and Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC)
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,030106 microbiology ,Population ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Placebo ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,law ,Interquartile range ,Intensive care ,Internal medicine ,medicine ,Clinical endpoint ,030212 general & internal medicine ,education ,Severe acute respiratory syndrome coronavirus 2 ,education.field_of_study ,Coronavirus disease 2019 ,business.industry ,Hydroxychloroquine ,General Medicine ,Placebo-controlled ,3. Good health ,Infectious Diseases ,Relative risk ,business ,medicine.drug - Abstract
Objectives To determine whether hydroxychloroquine decreases the risk of adverse outcome in patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk of worsening. Methods We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening: need for supplemental oxygen, age ≥75 years, age between 60 and 74 years and presence of at least one co-morbidity. Severely ill patients requiring oxygen therapy >3 L/min or intensive care were excluded. Eligible patients were randomized in a 1:1 ratio to receive either 800 mg hydroxychloroquine on day 0 followed by 400 mg per day for 8 days or a placebo. The primary end point was a composite of death or start of invasive mechanical ventilation within 14 days following randomization. Secondary end points included mortality and clinical evolution at days 14 and 28, and viral shedding at days 5 and 10. Results The trial was stopped after 250 patients were included because of a slowing down of the pandemic in France. The intention-to-treat population comprised 123 and 124 patients in the placebo and hydroxychloroquine groups, respectively. The median age was 77 years (interquartile range 58–86 years) and 151/250 (60.4%) patients required oxygen therapy. The primary end point occurred in 9/124 (7.3%) patients in the hydroxychloroquine group and 8/123 (6.5%) patients in the placebo group (relative risk 1.12; 95% CI 0.45–2.80). The rates of positive SARS-CoV-2 RT-PCR tests at days 5 and 10 were 72.8% (75/103) and 57.1% (52/91) in the hydroxychloroquine group, versus 73.0% (73/100) and 56.6% (47/83) in the placebo group, respectively. No difference was observed between the two groups in any of the other secondary end points. Conclusion In this underpowered trial involving mainly older patients with mild to moderate COVID-19, patients treated with hydroxychloroquine did not experience better clinical or virological outcomes than those receiving the placebo. Trial registration ClinicalTrials.gov Identifier: NCT04325893 ( https://clinicaltrials.gov/ct2/show/NCT04325893 ).
- Published
- 2020
16. Rabies Postexposure Prophylaxis Noncompletion After Dog Bites: Estimating the Unseen to Meet the Needs of the Underserved
- Author
-
Philippe Buchy, Philippe Dussart, Hervé Bourhy, Jean-Yves Mary, Yiksing Peng, Sotheary In, Sovann Ly, Sophie Blanchi, Chun Navy Taing, Chanthy Hing, Julien Cappelle, Sowath Ly, Malen Chan, Arnaud Tarantola, Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP), Unité Mixte de Recherche d'Épidémiologie des maladies Animales et zoonotiques (UMR EPIA), Institut National de la Recherche Agronomique (INRA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS), Ministry of Health [Phnom Penh], Dynamique des Lyssavirus et Adaptation à l'Hôte (DyLAH), Institut Pasteur [Paris], GlaxoSmithKline, Glaxo Smith Kline, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP), Unité de recherche d'Épidémiologie Animale (UEA), Institut National de la Recherche Agronomique (INRA), Dynamique des Lyssavirus et Adaptation à l'Hôte, and Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)
- Subjects
Male ,Rural Population ,dogs ,rabies ,Logistic regression ,L73 - Maladies des animaux ,Health Services Accessibility ,WHO ,0302 clinical medicine ,access ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Epidemiology ,Analyse du risque ,030212 general & internal medicine ,Bites and Stings ,education.field_of_study ,U10 - Informatique, mathématiques et statistiques ,vaccine Abbreviations: IPC ,Middle Aged ,Prophylaxie des maladies ,3. Good health ,Vaccination ,Épidémiologie ,S50 - Santé humaine ,observance ,cardiovascular system ,RPC ,Female ,epidemiology ,Cambodia ,Post-Exposure Prophylaxis ,Rural population ,postexposure prophylaxis ,circulatory and respiratory physiology ,Adult ,medicine.medical_specialty ,rabies index ,Patient Dropouts ,Adolescent ,Vaccin ,RI ,030231 tropical medicine ,Population ,education ,World Health Organization ,Rage ,03 medical and health sciences ,Young Adult ,Environmental health ,medicine ,Animals ,Humans ,medically underserved area ,Cartographie ,business.industry ,medicine.disease ,Rabies virus ,Rabies Prevention Center ,Attributable risk ,PEP ,Institut Pasteur du Cambodge ,Rabies ,Residence ,business - Abstract
International audience; Postexposure prophylaxis (PEP) prevents human rabies and is accessible in Cambodia principally in Phnom Penh, the capital. Timely, affordable access to PEP is a challenge for the mainly rural population. We aimed to identify districts independently associated with PEP noncompletion to position frontline vaccination centers. We analyzed the 2009–2013 database at the Rabies Prevention Center at the Institut Pasteur du Cambodge, Phnom Penh. Logistic regressions identified nongeographic determinants of PEP noncompletion as well as the districts that were independently associated with noncompletion after adjustment for these determinants. The influence of distance by road was estimated using a boosted regression-trees model. We computed a population attributable fraction (rabies index (RI)) for each district and developed a map of this RI distribution. A cartographic analysis based on the statistic developed by Getis and Ord identified clusters of high-RI districts. Factors independently associated with noncompletion were pa-tients' district of residence, male sex, age 15–49 years, initial visit during rice harvest, the dog's status (culled or disappeared), and a prescribed PEP protocol requiring more than 3 PEP sessions (4 or 5). Four clusters of high-RI districts were identified using this analytical strategy, which is applicable to many vaccination or other health services. Positioning frontline PEP centers in these districts could significantly widen access to timely and adequate PEP.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.